Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Allergan, Inc.    AGN   US0184901025

ALLERGAN, INC. (AGN)

24
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Allergan, Inc. : CORRECT : Allergan 4Q Net Rose 6.3%, Margins Improve; R&D Costs Higher

02/02/2012 | 11:30am US/Eastern
Recommend:
0

("Allergan 4Q Net Falls 6.3% On Higher R&D Costs; Margins Improve," at 9:41 a.m. EST, misstated the earnings change direction in the headline and first and fourth paragraphs. A corrected version follows:)

Allergan Inc.'s (>> Allergan, Inc.) fourth-quarter earnings rose 6.3% and margins improved, though the Botox maker saw a sharp rise in research-and-development costs and booked one-time items.

The company also forecast current-quarter earnings of 84 cents to 86 cents a share on revenue of $1.34 billion and $1.39 billion, while analysts surveyed by Thomson Reuters expect 91 cents on $1.38 billion. Allergan also expects full-year earnings of $4.13 to $4.19 a share on revenue between $5.65 billion and $5.85 billion. Analysts were expecting $4.21 a share on $5.89 billion for the year.

Allergan has seen its revenue grow for more than two years, aided by surging sales of the wrinkle-fighting drug Botox. The injectable neurotoxin is approved for both cosmetic use and for treating various medial issues. Allergan has been expanding its pipeline of late, such as buying Vicept Therapeutics Inc., the developer of a cream to treat rosacea, and striking a deal with Map Pharmaceuticals Inc. (>> MAP Pharmaceuticals Inc.) to jointly promote Map's experimental migraine treatment Levadex. Allergan's Botox was also approved in August as a treatment for urinary incontinence in patients with neurologic conditions such as spinal-cord injury and multiple sclerosis.

Allergan reported a profit of $279.8 million, or 90 cents a share, up from $263.1 million, or 85 cents, a year earlier. Excluding items such as amortization, realignment and litigation costs, earnings rose to $1 a share from 88 cents. Revenue jumped 7.1% to $1.4 billion.

Its October projection was earnings of 97 cents to 99 cents a share on sales of $1.33 billion to $1.41 billion.

Operating margin rose to 29.2% from 28.1%.

Research and development costs jumped 13% to $226.4 million.

Specialty pharmaceutical sales--which make up the bulk of Allergan's revenue--rose 8.9%. Revenue from the medical-device segment, which includes breast implants and the Lap-Band System for obesity, decreased 1%.

Shares were trading 1.9% lower at $85.63 premarket. The stock has risen 4.7% over the past three months through Wednesday's close.

 
   -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com 

Stocks mentioned in the article : Allergan, Inc., MAP Pharmaceuticals Inc.
Recommend :
0
React to this article
Latest news on ALLERGAN, INC.
40m ago ALLERGAN : Valeant to replace three board members; Allergan adopts poison pill d..
5h ago ALLERGAN : Entry into a Material Definitive Agreement, Material Modification to ..
5h agoDJACKMAN : Poison Pill Is Way for Allegan to Explore Alternatives -CNBC
6h ago ALLERGAN : Valeant CEO 'disappointed' in Allergan poison pill: CNBC
9h ago ALLERGAN : S&P 500 tops its longest rally in 2014 in closing
1d ago ALLERGAN : Adopts One-Year Stockholder Rights Plan
1d ago Activist investors see Ackman-Valeant deal as a model to follow
1d ago Novartis, Valeant bids herald new deal-making era for pharma
1d agoDJALLERGAN PURSUER VALEANT : A Drug Maker With Little Patience for Science
1d agoDJMARKET SNAPSHOT : U.S. Stocks Gain; S&P 500 Extends Streak To Six
Advertisement
Chart
Duration : Period :
Allergan, Inc. Technical Analysis Chart | AGN | US0184901025 | 4-Traders
Income Statement Evolution
Allergan, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF